Alert detail
LCD L39987: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis — WPS
What changed
New LCD for hereditary amyloidosis testing impacts billing.
Who’s affected: Neurology billing teams · Effective: August 17, 2025
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 5 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.